Gene · 4593
Papers3,141
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,141
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis. | Eur J Neurol | 2025 | 39624955 | PubTator, text mining | PubMed |
| Online estimation method for extreme learning machine with kernels based on the multi-innovation theory and intelligent optimization strategy. | ISA Trans | 2025 | 39537462 | PubTator, text mining | PubMed |
| Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study. | Neurol Sci | 2025 | 39503950 | PubTator, text mining | PubMed |
| Prevalence, Incidence, and Mortality of Myasthenia Gravis and Myasthenic Syndromes: A Systematic Review. | Neuroepidemiology | 2025 | 39380477 | PubTator, text mining | PubMed |
| Efgartigimod Successfully Ameliorated Acute Exacerbation of Myasthenia Gravis with Anti-muscle-specific Kinase Antibodies. | Intern Med | 2025 | 39111891 | PubTator, text mining | PubMed |
| A clinical perspective on muscle specific kinase antibody positive myasthenia gravis. | Front Immunol | 2024 | 39703505 | PubTator, text mining | PubMed |
| Advances in B Cell Targeting for Treating Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis. | Immunotargets Ther | 2024 | 39678139 | PubTator, text mining | PubMed |
| Genome-wide association studies of ischemic stroke based on interpretable machine learning. | PeerJ Comput Sci | 2024 | 39650478 | PubTator, text mining | PubMed |
| Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation. | Front Neurol | 2024 | 39628891 | PubTator, text mining | PubMed |
| Surgical treatment of thymic epithelial tumor and myasthenia gravis. | Front Surg | 2024 | 39624461 | PubTator, text mining | PubMed |
| Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review. | Front Immunol | 2024 | 39624088 | PubTator, text mining | PubMed |
| Complications of Long COVID: Unraveling a Case of Very-Late-Onset Myasthenia Gravis. | Cureus | 2024 | 39479090 | PubTator, text mining | PubMed |
| Isolated Respiratory Failure as the Presenting Symptom of Muscle-Specific Kinase Myasthenia Gravis: A Case Report and Literature Review. | Case Rep Neurol | 2024 | 39474296 | PubTator, text mining | PubMed |
| Grilled nux vomica alleviates myasthenia gravis by inhibiting the JAK2/STAT3 signaling pathway: a study in a mice model. | Eur J Med Res | 2024 | 39434147 | PubTator, text mining | PubMed |
| [Efficacy and safety of rituximab in the treatment of pediatric myasthenia gravis]. | Zhonghua Er Ke Za Zhi | 2024 | 39429076 | PubTator, text mining | PubMed |
| Clinical Characteristics of Double Seropositive Myasthenia Gravis. | Neurol India | 2024 | 39428782 | PubTator, text mining | PubMed |
Laryngeal Myasthenia Gravis in Voice Patients: Clinical, Serologic, and Neuromuscular Characterization of Seronegative Patients for Antibodies Against the Acetylcholine Receptor and Muscle-Specific Kinase. | J Voice | 2024 | 39419706 | PubTator, text mining | PubMed |
| New treatment strategies in Myasthenia gravis. | Rev Neurol (Paris) | 2024 | 39379218 | PubTator, text mining | PubMed |
| The changing landscape of autoantibody testing in myasthenia gravis in the setting of novel drug treatments. | Clin Biochem | 2024 | 39357636 | PubTator, text mining | PubMed |
Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. | Ther Adv Neurol Disord | 2024 | 39297052 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4593/papers?page=11